RecruitingGlioblastomaAstrocytomaVenous Thromboembolism

Venous Thromboembolism Prevention in Outpatients With Glioma

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

This is an open label study of apixaban for venous thromboembolism prevention in patients with newly diagnosed grade 4 glioma.

Sponsor: University of Vermont Medical Center

✓ Histologic diagnosis of malignant glioma, World Health Organization (WHO) grade 4, including glioblastoma and astrocytoma, based on recent biopsy or resection.
✓ Age 18 and old
✓ Karnofsky performance status (KPS) 60-100
✓ Acceptable labs, including platelets of greater than or equal to 100,000, glomerular filtration rate (GFR) greater than or equal to 25.
✓ Ability to provide informed consent.
✓ Planning for treatment with radiation and chemotherapy.

✕ Evidence of deep venous thrombosis (DVT), pulmonary embolism (PE), or cerebral vein thrombosis (CVT) within 6 months prior to enrollment on the study.
✕ Pregnancy.
✕ Significant bleeding risk including: history of symptomatic intracranial hemorrhage, active bleeding at time of study registration, clinically significant bleeding within 14 days of study registration, intracranial trauma in the past 6 months, including stroke or traumatic brain injury, major surgery or major procedure within 48 hours.
✕ Allergy to apixaban or contraindication to prophylactic anticoagulation. Contraindications include patients who are currently on unfractionated heparin, low molecular weight heparin, heparin derivatives (examples: fondaparinux), or other direct oral anticoagulants (examples: dabigatran, edoxaban, rivaroxaban), who are either unable or unable to discontinue these agents in favor of the investigational drug. Apixaban is also contraindicated in patients who are on strong CYP3A4 inhibitor and P-glycoprotein inhibitors.
✕ Indication for full anticoagulation (i.e. atrial fibrillation, mechanical valve, etc.).
✕ Estimated life expectancy of \<3 months.

Burlington

Source: ClinicalTrials.gov · NCT05683808 · last updated 2026-01-30